Atlas Trials

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Clinical trial NCT03519945 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03519945
Sponsor
Eli Lilly and Company
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Ulcerative Colitis
Start date
2018-07-18
Primary completion
2026-03-04
Enrollment
1058

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.